Bionano Genomics announced that it has received a letter from the staff of the Listing Qualifications department of the Nasdaq Stock Market notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market . As previously announced, the Company was notified by Nasdaq on May 30 3 that it was not in compliance with the Minimum Bid Price Requirement. The notification letter noted that for the last 10 consecutive business days, from August 7 to August 18 the closing bid price of the Company’s common stock has been at $1.00 per share or greater, and thus the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
- Bionano Genomics receives CAP accreditation for clinical laboratory
- Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory
- Bionano Genomics announces CFO transition, appointment of Kama as CFO
- Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer